Frontal fibrosing alopecia (FFA)

Meet the patient

A 64-year-old woman is sent by her hairdresser, who has watched her frontal hairline creep back over four years. Her old driving-licence photograph shows a hairline three centimetres further forward than today. On the leading edge, individual follicles sit in pink halos under white scale; a few lonely terminal hairs stand marooned in the smooth, shiny receded band; and the outer third of both eyebrows has gone.[1]

Two questions frame every FFA consultation: is the disease still active? (look for perifollicular erythema and hyperkeratosis at the leading edge) and how fast is it marching? (measure recession from the glabella against old photographs). The answers decide whether to escalate or reassure.[1]

Why scarring makes this a one-way disease

Once a follicle is destroyed and replaced by fibrous tissue, it cannot regenerate. That single biological fact is the whole reason FFA is treated aggressively and early, and the whole reason you must never promise regrowth.[1][2]

The inflammatory attack targets follicular stem cells in the bulge region — the niche at the arrector pili insertion that repopulates the follicular matrix every cycle. Burn the stem cells and the follicle loses its capacity to start a new anagen phase; the space fills with dense collagen and no follicular ostia remain. The smooth, shiny receded band is the visible signature of that scar.[1]

The mantra: halt the march, never promise regrowth. Every treatment decision is about protecting the hair the patient still has.[2]

The pathogenesis in four steps — T-L-D-F

FFA is a lymphocytic scarring alopecia driven by a lichenoid interface dermatitis around the upper follicle. The cascade runs trigger to scar in four linked steps, though the initiating antigen remains unknown.[4]

[1]

The striking anatomical correlation — disease begins precisely where facial cosmetics and sunscreens are applied to the forehead and hairline — is the engine of the leading environmental hypothesis. The temporal correlation between the widespread adoption of daily sunscreen use among Caucasian women from the 1990s and the dramatic global rise in FFA is striking, but a definitive causal link and a specific culprit ingredient have not been proven.[4]

The lymphocytic camp — and the discriminator from the pus-formers

FFA belongs to the lymphocytic subgroup of primary cicatricial alopecias. That membership decides everything downstream: the morphology shows perifollicular erythema and scale (not pustules), and the treatment targets lymphocytes (not bacteria).[3][5]

[1]

One-line discriminator: no pus at the margin means lymphocytic, and in a post-menopausal woman with a receding frontal band that means FFA until proven otherwise.[3]

The clinical picture — and the lonely hair

The hallmark is a slowly advancing, symmetric band of frontotemporal recession, typically half a centimetre to three centimetres wide at presentation, with the hair density behind the band preserved. The disease attacks the leading edge, not the whole scalp.[1]

Three signs confirm active disease at the margin and earn marks in the viva:[5]

• Perifollicular erythema and hyperkeratosis — pink halos and white scale cuffs around emerging shafts; the trichoscopic correlate of active inflammation and the place to aim intralesional steroid.
• Lonely hairs — isolated terminal shafts marooned in the smooth receded band, survivors of the original hairline. Their presence separates FFA from traction alopecia, where they are absent.
• Eyebrow loss — partial or complete, in roughly 50 to 80 percent, beginning laterally. Crucially it may precede the scalp loss by months or years, and the combination of eyebrow loss plus frontal recession in a post-menopausal woman is close to pathognomonic.[1]

Everyone forgets body hair. Loss of axillary, pubic, and limb hair reflects the systemic nature of the follicular autoimmune process and is easily missed unless you ask; small facial papules on temples and cheeks mark the FFA-plus phenotype and a more aggressive course.[1]

[1]

The face-off — FFA versus its frontal-recession mimics

Progressive frontotemporal recession has a short differential, and three bedside features settle most of it: eyebrow loss, perifollicular erythema, and the demographic.[3][5]

[1]

One-line discriminator: eyebrow loss plus perifollicular erythema in a post-menopausal woman is FFA; the same frontal band in a young woman with a braid history is traction. When the picture does not fit — a pre-menopausal woman, a man, rapidly progressive recession, or plaques with follicular plugging — biopsy the active margin to exclude discoid lupus.[3]

Diagnose with the dermatoscope; biopsy the active margin

FFA is a clinical diagnosis with trichoscopic confirmation. Reach for the biopsy punch only when the picture is atypical or you need histology before committing to long-term systemic therapy.[3][5]

The four trichoscopic findings to reproduce verbatim:[5]

• Perifollicular erythema — pink-red halos around shafts at the active margin; the most reliable sign of activity.
• Perifollicular hyperkeratosis — white scale and keratotic plugs cuffing the shaft.
• Lonely hair — a single terminal shaft in smooth scarred skin.
• Absent follicular ostia with white dots — smooth shiny skin with no follicular openings, the hallmark of scarring.

[5]

The classic trap: biopsying the burnt-out centre. The scarred centre yields only fibrosis and is non-diagnostic. Always biopsy the active margin, where perifollicular erythema is visible — that is where the diagnostic lichenoid infiltrate lives.[3]

On histology expect a perifollicular lymphocytic (lichenoid) infiltrate around the upper follicle, basaloid vacuolar degeneration of the outer root sheath, loss of sebaceous glands, and concentric lamellar fibrosis progressing to complete follicular replacement by collagen. Neutrophils, plasma cells, and organisms are absent — which is exactly what separates FFA from folliculitis decalvans.[1]

Direct immunofluorescence is negative in FFA (occasional Civatte bodies only), which is how you separate it from discoid lupus, where a positive lupus band (granular IgG, IgM, and C3 along the dermo-epidermal junction) settles the question. Order DIF whenever DLE is in the differential.[3]

The treatment — halt the march, never promise regrowth

There are no randomised trials in FFA; every recommendation rests on expert consensus, retrospective series, and extrapolation from lichen planopilaris. Disease activity (perifollicular erythema and hyperkeratosis) and the rate of progression guide how hard you treat.[1][2]

[1]

First line — topical and intralesional, plus trigger removal

Potent topical corticosteroid (clobetasol propionate 0.05 percent lotion or foam once daily to the active margin for four to six weeks, then taper) damps the perifollicular inflammation at the leading edge. Add intralesional triamcinolone acetonide 10 mg per mL into the active margin, 0.05 to 0.1 mL per site at one-centimetre intervals, repeated every four to six weeks for three to six sessions, and topical minoxidil 5 percent twice daily (or low-dose oral minoxidil) to thicken surviving shafts.[1]

Tell every patient to stop applying leave-on facial products and sunscreens to the forehead and hairline, and to use physical barriers — hats, caps, clothing — for sun protection instead. The causal link is unproven but the risk of stopping is nil and the potential benefit is real.[4]

First-line systemic — the antimalarial and the androgen blocker

For progressive disease, two systemic agents anchor first line.[1][3]

• Hydroxychloroquine 200 to 400 mg daily (typically 200 mg twice daily) is the traditional antimalarial first step, with an eight to twelve week lag to effect and mandatory baseline plus annual ophthalmological screening for retinal toxicity.
• 5-alpha-reductase inhibitors — finasteride 1 to 5 mg daily or dutasteride 0.5 mg daily — are now regarded by many specialists as the most consistently effective systemic agents, stabilising disease in roughly 50 to 70 percent despite the disease striking post-menopausal women with low androgen levels. The mechanism is local dihydrotestosterone reduction in the follicle, not systemic androgen effects.[1]

Consultant confession: the most counterintuitive win in FFA is that the drugs built for male pattern baldness work best in a disease of post-menopausal women. Block local DHT in the follicle and the inflammatory milieu quietens — even when systemic androgen levels are already low.[1]

Second line and refractory

When first-line systemic therapy fails, the ladder climbs to doxycycline 100 mg twice daily (anti-inflammatory, matrix-metalloproteinase inhibition), pioglitazone 15 to 30 mg daily (PPAR-gamma agonist), and for truly refractory disease mycophenolate mofetil 500 mg to 1 g twice daily or methotrexate 10 to 25 mg once weekly with folic acid, under blood-count and liver-function monitoring.[1]

Hair transplant — only when the fire is out

Follicular unit transplantation can reconstruct the hairline, but only in burnt-out disease. The disease must be clinically and trichoscopically inactive for at least two years before surgery, because surgical trauma into active disease Koebnerises — it reactivates the inflammatory process and destroys the grafts. Even then, graft survival is often disappointing in the scarred, poorly vascularised recipient bed, and the patient must understand this is cosmetic reconstruction, not a cure.[2]

[1]

Pre-menopausal women, men, and skin of colour

In a pre-menopausal woman, the same diagnosis is rare and finasteride or dutasteride is strictly teratogenic — anti-androgen effect on a male fetus — so never prescribe it without robust contraception, and prefer hydroxychloroquine and topical therapy. The same rule governs pregnancy and breastfeeding: avoid 5-alpha-reductase inhibitors, tetracyclines, and retinoids; moderate topical steroids and tacrolimus are safe.[1]

Male FFA is rare (roughly 15 percent of cases), presents with more temple involvement and less eyebrow loss, and is easily mislabelled androgenetic alopecia. The discriminator is the band-like frontotemporal recession with perifollicular erythema, and 5-alpha-reductase inhibitors work well — watch for sexual side effects.[1]

In skin of colour, post-inflammatory hyperpigmentation in the receded zone may be the presenting complaint and the scarring can run keloidal. Avoid very potent topical steroids on facial skin (hypopigmentation, atrophy) and address pigment with sun protection and topical agents once the inflammation is controlled.[1]

The pitfalls that scar hairlines

Five pitfalls account for most of the harm in FFA, and every one of them is preventable.[1]

Ward-round test

A 62-year-old woman has three years of progressive frontal hairline recession and eyebrow loss. Trichoscopy shows perifollicular erythema and hyperkeratosis at the active margin, with lonely hairs in the receded zone. Diagnosis, and the single most effective systemic treatment?

This is classic frontal fibrosing alopecia — post-menopausal woman, progressive frontotemporal recession, eyebrow loss, perifollicular erythema on trichoscopy. The most consistently effective systemic agent is a 5-alpha-reductase inhibitor — finasteride 1 to 5 mg daily or dutasteride 0.5 mg. Treatment halts progression; the existing hair loss is irreversible scarring.[1]

Why must you biopsy the active margin and not the smooth receded centre in suspected FFA?

The burnt-out centre contains only fibrosis and is non-diagnostic. The active margin, where perifollicular erythema is visible, is where the diagnostic perifollicular lymphocytic lichenoid infiltrate with basaloid degeneration and loss of sebaceous glands lives. Biopsying the centre wastes the punch and misses the diagnosis.[3]

A 58-year-old with burnt-out FFA wants a hair transplant to restore her hairline. What is the single non-negotiable precondition, and why?

The disease must be clinically and trichoscopically inactive for at least two years before surgery. Transplanting into active disease risks Koebnerisation — the surgical trauma reactivates the lichenoid inflammation and destroys the grafts. Even in inactive disease, graft survival is often disappointing because the scarred recipient bed is poorly vascularised.[2]

Separate FFA from traction alopecia at the bedside in one line.

FFA affects post-menopausal women and shows perifollicular erythema, lonely hairs, and eyebrow loss; traction alopecia affects younger women with a tight-hairstyle history, has no eyebrow loss, and shows no perifollicular erythema in the late phase. The eyebrow loss plus the demographic is the fastest discriminator.[1]

References

1. [1]Messenger AG, Asfour L, Harries M Frontal Fibrosing Alopecia: An Update Am J Clin Dermatol, 2025.PMID 39699852
2. [2]Krzesłowska WJ, Woźniacka A The Frontal Fibrosing Alopecia Treatment Dilemma J Clin Med, 2024.PMID 38610902
3. [3]Fechine COC, Valente NYS, Romiti R Lichen planopilaris and frontal fibrosing alopecia: review and update of diagnostic and therapeutic features An Bras Dermatol, 2022.PMID 35379508
4. [4]Miao YJ, Jing J, Du XF, et al. Frontal fibrosing alopecia: A review of disease pathogenesis Front Med (Lausanne), 2022.PMID 35957858
5. [5]Porriño-Bustamante ML, Fernández-Pugnaire MA, Arias-Santiago S Frontal Fibrosing Alopecia: A Review J Clin Med, 2021.PMID 33919069